title: copy number variation analysis in familial BRCA1/2-negative Finnish breast and ovarian cancer.
abstract: BACKGROUND
  Inherited factors predisposing individuals to breast and ovarian cancer are largely unidentified in a majority of families with hereditary breast and ovarian cancer (HBOC). We aimed to identify germline copy number variations (CNVs) contributing to HBOC susceptibility in the Finnish population.
  
  
  METHODS
  A cohort of 84 HBOC individuals (negative for BRCA1/2-founder mutations and pre-screened for the most common breast cancer genes) and 36 healthy controls were analysed with a genome-wide SNP array. CNV-affecting genes were further studied by Gene Ontology term enrichment, pathway analyses, and database searches to reveal genes with potential for breast and ovarian cancer predisposition. CNVs that were considered to be important were validated and genotyped in 20 additional HBOC individuals (6 CNVs) and in additional healthy controls (5 CNVs) by qPCR.
  
  
  RESULTS
  An intronic deletion in the EPHA3 receptor tyrosine kinase was enriched in HBOC individuals (12 of 101, 11.9%) compared with controls (27 of 432, 6.3%) (OR = 1.96; P = 0.055). EPHA3 was identified in several enriched molecular functions including receptor activity. Both a novel intronic deletion in the CSMD1 tumor suppressor gene and a homozygous intergenic deletion at 5q15 were identified in 1 of 101 (1.0%) HBOC individuals but were very rare (1 of 436, 0.2% and 1 of 899, 0.1%, respectively) in healthy controls suggesting that these variants confer disease susceptibility.
  
  
  CONCLUSIONS
  This study reveals new information regarding the germline CNVs that likely contribute to HBOC susceptibility in Finland. This information may be used to facilitate the genetic counselling of HBOC individuals but the preliminary results warrant additional studies of a larger study group.
authors: Institute of Biomedical Technology/BioMediTech, University of Tampere and Fimlab Laboratories, Tampere, Finland.
authors: Kirsi M
authors: KM
authors: Kuusisto
authors: Oyediran
authors: O
authors: Akinrinade
authors: Mauno
authors: M
authors: Vihinen
authors: Minna
authors: M
authors: Kankuri-Tammilehto
authors: Satu-Leena
authors: SL
authors: Laasanen
authors: Johanna
authors: J
authors: Schleutker
mesh_terms: D000328:Adult; D000368:Aged; D016022:Case-Control Studies; D056915:DNA Copy Number Variations; D005260:Female; D005387:Finland; D017353:Gene Deletion; D020440:Gene Duplication; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D020022:Genetic Predisposition to Disease; D055106:Genome-Wide Association Study; D018095:Germ-Line Mutation; D061325:Hereditary Breast and Ovarian Cancer Syndrome / Q000235:genetics* / Q000473:pathology; D006801:Humans; D008875:Middle Aged; D010375:Pedigree; D020641:Polymorphism, Single Nucleotide; D015203:Reproducibility of Results; D044465:White People / Q000235:genetics*; D055815:Young Adult
references: Annu Rev Med. 2010;61:437-55
references: 20059347
references: PLoS Genet. 2012;8(6):e1002734
references: 22737080
references: BMC Med Genet. 2008 Jun 27;9:56
references: 18588689
references: J Med Genet. 2005 May;42(5):e31
references: 15863663
references: Nature. 2009 Jun 18;459(7249):987-91
references: 19536264
references: Cancer Biol Ther. 2009 May;8(10):907-16
references: 19276661
references: Nat Rev Cancer. 2010 Mar;10(3):165-80
references: 20179713
references: Hum Mutat. 2003 Jun;21(6):654
references: 14961556
references: Sci Transl Med. 2012 Feb 22;4(122):122ra23
references: 22357538
references: BMC Cancer. 2008 May 26;8:146
references: 18501021
references: Nat Genet. 1996 Mar;12(3):333-7
references: 8589730
references: Science. 1994 Oct 7;266(5182):66-71
references: 7545954
references: J Gastroenterol. 2012 Jul;47(7):785-94
references: 22350700
references: Int J Cancer. 2011 Oct 1;129(7):1635-42
references: 21128281
references: Breast Cancer Res Treat. 2010 Jun;121(3):555-63
references: 19669408
references: BMC Med Genet. 2011 Oct 11;12:134
references: 21989022
references: J Mammary Gland Biol Neoplasia. 2008 Jun;13(2):259-68
references: 18454307
references: Nucleic Acids Res. 2007;35(6):2013-25
references: 17341461
references: Nat Rev Cancer. 2005 May;5(5):341-54
references: 15864276
references: Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):7952-7
references: 11438741
references: Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):50-3
references: 21454190
references: Nature. 2007 Mar 15;446(7133):316-9
references: 17287723
references: Breast Cancer Res. 2012 Feb 07;14(1):R24
references: 22314128
references: Hum Mol Genet. 1997 Dec;6(13):2309-15
references: 9361038
references: Anticancer Res. 2011 May;31(5):1703-11
references: 21617229
references: J Clin Pathol. 2011 Jun;64(6):498-503
references: 21415057
references: Nat Rev Genet. 2006 Feb;7(2):85-97
references: 16418744
references: Science. 2008 Apr 25;320(5875):539-43
references: 18369103
references: Nucleic Acids Res. 2005 Jul 1;33(Web Server issue):W741-8
references: 15980575
references: Nature. 2010 Jul 15;466(7304):368-72
references: 20531469
references: Science. 2007 Feb 9;315(5813):848-53
references: 17289997
references: Genome Res. 2007 Nov;17(11):1665-74
references: 17921354
references: Am J Hum Genet. 2007 Sep;81(3):559-75
references: 17701901
references: Hum Mol Genet. 2011 Aug 15;20(16):3278-88
references: 21616938
references: Breast Cancer Res. 2011 Feb 28;13(1):R20
references: 21356067
references: Cancer Res. 2009 Mar 15;69(6):2176-9
references: 19258504
references: Cell Mol Life Sci. 2008 Nov;65(21):3366-82
references: 18818873
references: Am J Hum Genet. 2005 Jan;76(1):8-32
references: 15549674
references: Cell. 2008 Apr 4;133(1):38-52
references: 18394988
references: Am J Hum Genet. 2002 Aug;71(2):432-8
references: 12094328